Clinical Trials

30 enrolled

Pancreatic Neoplasms

NCT03421353 2024-08-21

AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer

76 enrolled

Other solid neoplasm

Advanced Solid Tumours

NCT03435250 2024-07-25

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Phase 1 Active not recruiting

123 enrolled

Lymphoid

Lymphoma

NCT03530397 2024-06-24

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

401 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT03928314 2023-12-15

Study of ORIC-101 in Combination With Anticancer Therapy

83 enrolled

Other solid neoplasm

Solid Tumor

NCT02231723 2023-11-18

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

139 enrolled

Pancreatic cancer, adult, Digestive System Neoplasms, Endocrine Gland Neoplasms, Adenoma, Islet Cell, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Pancreatic Ductal

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

7 enrolled

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

NCT04247126 2023-10-27

A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

BreastGastrointestinalThoracic

105 enrolled

Breast Neoplasms, Pancreatic Neoplasms, Small Cell Lung Carcinoma

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

DermatologicHead & NeckLymphoidThoracic

159 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT04584112 2023-03-15

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

83 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04196283 2023-02-27

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasms

NCT04132817 2022-12-02

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

12 enrolled

Breast

Breast Neoplasms

NCT02857270 2022-11-22

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

DermatologicGastrointestinalThoracic

210 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT03412799 2022-05-25

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

50 enrolled

Pancreatic Neoplasms

NCT04282070 2021-12-21

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1 Unknown

91 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT02715531 2021-07-09

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

243 enrolled

Other solid neoplasm

Solid Tumor

NCT01633970 2020-10-08

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

240 enrolled

Tumor-Agnostic

Neoplasms

NCT02622074 2020-09-10

KEYNOTE 173

60 enrolled 26 charts

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT02050178 2020-09-09

Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

26 enrolled

Pancreatic Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

32 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01803282 2020-06-02

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

BreastGastrointestinalThoracic

236 enrolled 21 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02559674 2020-01-27

QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel

8 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT01478685 2019-11-12

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

GastrointestinalGenitourinaryGynecologicThoracic

169 enrolled

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Tumor Virus Infections, Carcinoma, Pancreatic Ductal

NCT02267707 2019-11-01

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

1 enrolled

Cholestasis, Pancreatic Neoplasms

NCT02574663 2019-10-02

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors